Please assess the completion status of the following clinical trial:

Trial Title: Multiple Ascending Dose Study for LCB01-0371

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Health Male between 20 and 45 years of age at the time of screening and a subject with body mass index (BMI) between 19 and 27~2. Medically healthy with no clinically significant screening results through Physical examination, x-ray, 12 lead ECG, Laboratory test~3. Able to donate blood during study period and follow visit.~4. Agree to continue to use a reliable method of birth control until 60 days after study completion.~5. Capable of giving written informed consent and Able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.~Exclusion Criteria:~1. History of liver, kidney, respiratory, musculoskeletal, endocrinologic, neuropsychiatric, hemato-oncologic, or cardiovascular problem(s).~2. History of gastrointestinal problem which is affect to absorption within 6 months from screening~3. History of hypersensitivity or clinically significant adverse drug reaction(s) to the LCB01-0371, same class of the study drugs (linezolid), or other drugs including aspirin and antibiotics.~4. History drug abuse or positive result of urine drug screening test for amphetamine, methamphetamine, barbiturate, cocaine, opiate, benzodiazepine, cannabinoid, methadone, etc.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- LCB01-0371 800mg (Type: EXPERIMENTAL): LCB01-0371 800mg
- LCB01-0371 1200mg (Type: EXPERIMENTAL): LCB01-0371 1200mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).